Kestra Private Wealth Services LLC Sells 13,993 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Key Points

• Kestra Private Wealth Services LLC has reduced its stake in Hims & Hers Health by 48.1%, selling 13,993 shares, and now holds 15,113 shares valued at $447,000.
• Insider trading activity includes Michael Chi selling 17,102 shares for over $1 million and CFO Oluyemi Okupe selling 23,107 shares valued at about $1.09 million.
• Analysts have revised price targets for Hims & Hers Health with a consensus target price of $39.83, while the stock retains a consensus "Hold" rating among investment analysts.

Kestra Private Wealth Services LLC reduced its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 48.1% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,113 shares of the company's stock after selling 13,993 shares during the period. Kestra Private Wealth Services LLC's holdings in Hims & Hers Health were worth $447,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of HIMS. Commonwealth Equity Services LLC boosted its position in shares of Hims & Hers Health by 111.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 58,894 shares of the company's stock valued at $1,424,000 after acquiring an additional 31,062 shares during the period. American Century Companies Inc. lifted its holdings in shares of Hims & Hers Health by 8.8% during the 4th quarter. American Century Companies Inc. now owns 140,758 shares of the company's stock worth $3,404,000 after acquiring an additional 11,425 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Hims & Hers Health during the fourth quarter worth about $861,000. LPL Financial LLC lifted its position in Hims & Hers Health by 1.0% in the 4th quarter. LPL Financial LLC now owns 97,958 shares of the company's stock worth $2,369,000 after buying an additional 980 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after acquiring an additional 2,020,722 shares during the last quarter. 63.52% of the stock is owned by institutional investors.

Insider Activity

In other Hims & Hers Health news, insider Michael Chi sold 17,102 shares of the stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $59.75, for a total transaction of $1,021,844.50. Following the sale, the insider directly owned 278,654 shares of the company's stock, valued at approximately $16,649,576.50. This trade represents a 5.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Oluyemi Okupe sold 23,107 shares of the firm's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total transaction of $1,091,805.75. Following the sale, the chief financial officer directly owned 63,222 shares in the company, valued at $2,987,239.50. The trade was a 26.77% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 788,368 shares of company stock valued at $42,410,254. Company insiders own 13.71% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on HIMS shares. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Piper Sandler reissued a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Truist Financial increased their price target on shares of Hims & Hers Health from $45.00 to $48.00 and gave the stock a "hold" rating in a research note on Thursday, July 17th. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, Morgan Stanley reissued an "equal weight" rating and issued a $40.00 target price on shares of Hims & Hers Health in a report on Wednesday, June 11th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health has a consensus rating of "Hold" and a consensus target price of $39.83.

Hims & Hers Health Price Performance

Shares of HIMS opened at $57.50 on Friday. The company has a 50-day moving average of $53.15 and a 200 day moving average of $42.88. The firm has a market capitalization of $12.87 billion, a price-to-earnings ratio of 83.33, a PEG ratio of 2.13 and a beta of 2.02. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The company's quarterly revenue was up 110.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.05 earnings per share. On average, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.